3/26
03:12 pm
tvgn
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
Low
Report
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
3/25
01:11 pm
tvgn
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
Low
Report
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
3/11
08:15 am
tvgn
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
3/10
12:46 pm
tvgn
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO [Yahoo! Finance]
Medium
Report
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO [Yahoo! Finance]
3/10
12:40 pm
tvgn
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
Medium
Report
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
3/7
04:17 pm
tvgn
Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel [Yahoo! Finance]
Medium
Report
Tevogen Bio's CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer's AI Discussion Panel [Yahoo! Finance]
3/7
04:09 pm
tvgn
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Medium
Report
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
3/4
08:03 am
tvgn
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $10.00 price target on the stock.
3/3
12:52 pm
tvgn
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
Medium
Report
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
2/28
01:17 pm
tvgn
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
Medium
Report
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
2/21
03:28 pm
tvgn
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
Low
Report
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
2/15
02:08 am
tvgn
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision [Yahoo! Finance]
Medium
Report
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision [Yahoo! Finance]
2/15
02:08 am
tvgn
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency [Yahoo! Finance]
Medium
Report
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency [Yahoo! Finance]
2/14
06:31 pm
tvgn
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
Medium
Report
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
2/14
01:16 pm
tvgn
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
Low
Report
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
2/14
11:52 am
tvgn
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
Medium
Report
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
2/13
06:07 pm
tvgn
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans [Yahoo! Finance]
Neutral
Report
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans [Yahoo! Finance]
2/13
04:34 pm
tvgn
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
Low
Report
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
2/11
07:04 pm
tvgn
Tevogen Bio Holdings Inc. (TVGN) Engages BARDA on AI-Driven ExacTcell Immunotherapy Advancements [Yahoo! Finance]
Medium
Report
Tevogen Bio Holdings Inc. (TVGN) Engages BARDA on AI-Driven ExacTcell Immunotherapy Advancements [Yahoo! Finance]
2/10
05:30 pm
tvgn
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
Low
Report
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
2/7
02:56 pm
tvgn
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
Low
Report
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
1/28
03:49 pm
tvgn
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
Medium
Report
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
1/27
02:24 pm
tvgn
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
Medium
Report
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
1/24
05:34 pm
tvgn
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
High
Report
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
1/23
07:53 pm
tvgn
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
Low
Report
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference